| Literature DB >> 25660394 |
J C Knight1, M Mosley, M R L Stratford, H T Uyeda, H A Benink, M Cong, F Fan, S Faulkner, B Cornelissen.
Abstract
A pretargeted imaging strategy based on the HaloTag dehalogenase enzyme is described. Here, a HaloTag-Trastuzumab conjugate has been used as the primary agent targeting HER2 expression, and three new radiolabelled HaloTag ligands have been used as secondary agents, two of which offer dual-modality (SPECT/optical) imaging capability.Entities:
Mesh：
Substances：
Year: 2015 PMID： 25660394 DOI： 10.1039/c4cc10265g
Source DB: PubMed Journal: Chem Commun (Camb) ISSN： 1359-7345 Impact factor: 6.222